Kenneth Olive

Assistant Dean of Graduate Curricula and Associate Professor of Medicine

Columbia University Irving Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (44)

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2025

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2025

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC) is believed to arise from the accumulation of a series of somatic mutations and is also frequently associated with pancreatic intraepithelial neoplasia (PanIN) lesions. However, there is still debate as to whether the cell type-of-origin of PanINs and PDACs in humans is acinar or ductal. As cell type identity is maintained epigenetically, DNA methylation changes during pancreatic neoplasia can provide a compelling perspective to examine this question. Here, we performed laser-capture microdissection on surgically resected specimens from 18 patients to isolate, with high purity, DNA for whole-genome bisulfite sequencing from four relevant cell types: acini, nonneoplastic ducts, PanIN lesions, and PDAC lesions. Differentially methylated regions (DMR) were identified using two complementary analytical approaches: bsseq, which identifies any DMRs but is particularly useful for large block-like DMRs, and informME, which profiles the potential energy landscape across the genome and is particularly useful for identifying differential methylation entropy. Both global methylation profiles and block DMRs clearly implicated an acinar origin for PanINs. At the gene level, PanIN lesions exhibited an intermediate acinar-ductal phenotype resembling acinar-to-ductal metaplasia. In 97.6% of PanIN-specific DMRs, PanIN lesions had an intermediate methylation level between normal and PDAC, which suggests from an information theory perspective that PanIN lesions are epigenetically primed to progress to PDAC. Thus, epigenomic analysis complements histopathology to define molecular progression toward PDAC. The shared epigenetic lineage between PanIN and PDAC lesions could provide an opportunity for prevention by targeting aberrantly methylated progression-related genes. Significance: Analysis of DNA methylation landscapes provides insights into the cell-of-origin of PanIN lesions, clarifies the role of PanIN lesions as metaplastic precursors to human PDAC, and suggests potential targets for chemoprevention.

Year:

2025

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Pancreatic ductal adenocarcinoma (PDAC) is believed to arise from the accumulation of a series of somatic mutations and is also frequently associated with pancreatic intraepithelial neoplasia (PanIN) lesions. However, there is still debate as to whether the cell-type-of-origin of PanINs and PDACs in humans is acinar or ductal. As cell type identity is maintained epigenetically, DNA methylation changes during pancreatic neoplasia can provide a compelling perspective to examine this question. Here, we performed laser-capture microdissection on surgically resected specimens from 18 patients to isolate, with high purity, DNA for whole-genome bisulfite sequencing from four relevant cell types: acini, non-neoplastic ducts, PanIN lesions, and PDAC lesions. Differentially methylated regions (DMRs) were identified using two complementary analytical approaches: bsseq, which identifies any DMRs but is particularly useful for large block-like DMRs; and informME which profiles the potential energy landscape across the genome and is particularly useful for identifying differential methylation entropy. Both global methylation profiles and block DMRs clearly implicated an acinar origin for PanINs. At the gene level, PanIN lesions exhibited an intermediate acinar-ductal phenotype resembling acinar-to-ductal metaplasia. In 97.6% of PanIN-specific DMRs, PanIN lesions had an intermediate methylation level between normal and PDAC, which suggests from an information theory perspective that PanIN lesions are epigenetically primed to progress to PDAC. Thus, epigenomic analysis complements histopathology to define molecular progression toward PDAC. The shared epigenetic lineage between PanIN and PDAC lesions could provide an opportunity for prevention by targeting aberrantly methylated progression-related genes.

Year:

2024

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (33)

Joseph G. Jurcic

Columbia University Irving Medical Center

UNITED STATES
View details

Prabhjot Mundi

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Peter Sims

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Hanina Hibshoosh

Professor of pathology at CUIMC

Columbia University

UNITED STATES
View details

Guy M. McKhann

Florence Irving Associate Professor of Neurological Surgery

Columbia University Irving Medical Center

UNITED STATES
View details

Ana Tergas

Rutgers, The State Univ. of NJ

UNITED STATES
View details

Tal Danino

Columbia University

UNITED STATES
View details

Alexander Muir

Assistant professor

University of Chicago

UNITED STATES
View details

agnes basseville

Institut de Cancérologie de l'Ouest

FRANCE
View details

Guarionex Joel DeCastro

Associate Professor

Columbia University

UNITED STATES
View details

Jason D. Wright

-

UNITED STATES
View details

Kasper Hansen

Professor

Johns Hopkins University

UNITED STATES
View details

Andrew Kung

Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mariano Alvarez

Chief Scientific Officer

KweHealth, LLC

UNITED STATES
View details

Gary K. Schwartz

Case Western Reserve University

UNITED STATES
View details

Andrew Lassman

Chief, Neuro-Oncology Division

Columbia University Irving Medical Center

UNITED STATES
View details

Marie Christin Hasselluhn

Associate Research Scientist

Columbia University Irving Medical Center

UNITED STATES
View details

Dawn L. Hershman

Columbia University Irving Medical Center

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Andrew Feinberg

Professor

Johns Hopkins University

UNITED STATES
View details

Katherine Crew

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Alfred I. Neugut

-

UNITED STATES
View details

Daniel Diolaiti

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Michael Kluger

Professor of Surgery

NYU Langone Health

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Tetsuhiro Harimoto

Dana-Farber Cancer Institute

UNITED STATES
View details

Eugene Douglass

Assistant Professor

University of Georgia

UNITED STATES
View details

Thomas Litman

Københavns Universitet

DENMARK
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Melissa K. Accordino

Columbia University

UNITED STATES
View details

Maryam Safari

Columbia University

UNITED STATES
View details

Susan E Bates

Columbia University Irving Medical Center

UNITED STATES
View details

Jeffrey Bruce

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center

UNITED STATES
View details